Market Overview

Abbott to Sell ALK's House Dust Mite Sublingual Allergy Immunotherapy Tablet in SE Asia

Share:

ALK (OTC: AKBLF) today announced an expansion of its partnership with Abbott under which Abbott will register and sell ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX(r) in Europe) in seven new growth markets in South-East Asia. 

Under the terms of the deal, Abbott gains exclusive rights to register, promote and distribute the product in Hong Kong, Malaysia, the Philippines, Singapore, South Korea, Taiwan and Thailand. ALK and Abbott will share the revenue generated in the territory where ALK will be responsible for product supply to Abbott. 

Regulatory submissions in the new markets are expected to be based upon ALK's regulatory filing which was approved by European authorities in August 2015. As a result, the first launches in South-East Asia are expected to take place from 2017 onwards. 

Since 2014, Abbott has had exclusive rights to commercialise ALK's SLIT-tablets covering HDM, grass, ragweed and tree allergies in Russia and other surrounding countries. 

Flemming Pedersen, EVP and CFO of ALK, said: "This new agreement between ALK and Abbott continues our strategic progress as we expand our commercial reach and work to globalise our most important new product

See full press release

Posted-In: News Contracts Press Releases

 

Related Articles (AKBLF)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleeding rates with long-term Elocta treatment

Earnings Scheduled For January 28, 2016